Skip to main content
. 2019 Nov 29;9:17958. doi: 10.1038/s41598-019-53238-7

Table 3.

Hazard ratios (HR) and 95% confidence intervals (CIs) for shoulder tendinopathy associated with statin use in women and men.

Statin use Age-adjusted HR (95% CI) Multivariable-adjusteda HR (95% CI) Age-adjusted HR (95% CI) Multivariable-adjusteda HR (95% CI)
Women Men
Never use 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference)
Ever use Any 1.23 (1.09–1.38) 1.14 (1.01–1.28) 1.48 (1.30–1.69) 1.41 (1.22–1.62)
Low dose 1.33 (1.08–1.64) 1.24 (1.00–1.53) 1.80 (1.38–2.36) 1.72 (1.31–2.26)
Medium dose 1.22 (1.07–1.38) 1.12 (0.98–1.28) 1.43 (1.25–1.65) 1.36 (1.18–1.58)
High dose 0.95 (0.36–2.54) 0.86 (0.32–2.30) 1.38 (0.84–2.26) 1.29 (0.78–2.13)
Simvastatin 1.19 (1.04–1.36) 1.10 (0.96–1.27) 1.41 (1.21–1.65) 1.36 (1.16–1.59)
Pravastatin 1.21 (0.65–2.27) 1.14 (0.61–2.13) 0.70 (0.22–2.17) 0.66 (0.21–2.05)
Fluvastatin NA NA NA NA
Atorvastatin 1.31 (1.08–1.59) 1.20 (0.99–1.46) 1.53 (1.25–1.88) 1.44 (1.17–1.78)
Rosuvastatin 1.46 (0.98–2.16) 1.33 (0.90–1.97) 2.17 (1.53–3.07) 2.04 (1.43–2.89)
Current use Any 1.50 (1.03–2.18) 1.41 (0.97–2.05) 1.50 (1.31–1.71) 1.43 (1.24–1.65)
0–1 years 1.42 (1.09–1.86) 1.32 (1.01–1.73) 2.13 (1.66–2.73) 2.05 (1.59–2.64)
1–2 years 1.62 (1.21–2.17) 1.51 (1.12–2.02) 1.64 (1.21–2.22) 1.57 (1.16–2.14)
2–3 years 1.15 (0.82–1.63) 1.06 (0.75–1.50) 1.48 (1.08–2.04) 1.39 (1.00–1.92)
>3 years 1.28 (1.07–1.52) 1.15 (0.96–1.38) 1.30 (1.09–1.53) 1.23 (1.03–1.47)
Former use Any 1.18 (0.87–1.60) 1.09 (0.80–1.49) 1.27 (0.88–1.83) 1.19 (0.83–1.72)
<1 year ago 1.02 (0.59–1.77) 0.97 (0.56–1.68) 0.99 (0.53–1.86) 0.93 (0.50–1.74)
1–2 years ago 1.44 (0.85–2.46) 1.37 (0.81–2.34) 0.84 (0.37–1.87) 0.79 (0.35–1.77)
>2 years ago 0.99 (0.62–1.58) 0.94 (0.59–1.51) 1.29 (0.78–2.12) 1.22 (0.74–2.02)

aMultivariable-adjusted model adjusted for age, BMI, METs, Charlson index, pack-years of smoking, energy intake, oral corticosteroid use, quinolone antibiotic use, diabetes mellitus, renal insufficiency and education level.